<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115335</article-id><article-id pub-id-type="publisher-id">ACM-42685</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_84767417.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  低浓度阿托品滴眼液在青少年近视防控中的疗效分析
  Efficacy Analysis of Low Concentration Atropine Eye Drops in Prevention and Control of Myopia in Adolescents
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>建初</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>顾</surname><given-names>晓波</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>莺</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>建勋</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蒋</surname><given-names>玉婷</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>无锡光正新视界眼科医院，江苏 无锡</addr-line></aff><aff id="aff3"><addr-line>无锡惠山区钱桥街道社区卫生服务中心，江苏 无锡</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2330</fpage><lpage>2334</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：研究分析0.01%低浓度阿托品滴眼液在青少年近视防控中的疗效及安全性。方法：选取2020年4月~2021年4月在门诊就诊的青少年中低度近视(&lt;−6.0D)近视者120例，用数字随机法进行分两组各60例；对照组给予维生素B12滴眼液常规方法治疗；研究组给予0.01%阿托品滴眼液治疗，对比两组的临床治疗效果和安全性。结果：研究组治疗效果显著优于对照组，差异有统计意义(P &lt; 0.01)；控制眼轴的增幅也小于对照组，差异有统计意义(P &lt; 0.01)；两组不良反应发生率相比较差异较小，无统计意义(P &gt; 0.05)。结论：0.01%阿托品滴眼液在青少年近视防控中的效果及安全性均较好，值得临床推广使用。
   Objective: To study and analyze the efficacy and safety of 0.01% low concentration atropine eye drops in prevention and control of juvenile myopia. Methods: A total of 120 adolescent patients with moderate and low myopia (&lt;−6.00D) from April 2020 to April 2021 were selected and randomly divided into two groups with 60 cases in each group. The control group was treated with vitamin B12 eye drops and the study group was treated with 0.01% atropine eye drops. The clinical efficacy and safety of the two groups were compared. Results: The treatment effect of the study group was significantly better than that of the control group; the difference was statistically significant (P &lt; 0.01). The increase of the control eye axis was also less than that of the control group, the difference was statistically significant (P &lt; 0.01); the difference in the incidence of adverse reactions between the two groups was small, there was no statistical significance (P &gt; 0.05). Conclusion: 0.01% atropine eye drops has good effect and safety in prevention and control of juvenile myopia, which is worthy of clinical application.
 
</p></abstract><kwd-group><kwd>0.01%阿托品，青少年，近视防控，有效性，安全性, 0.01% Atropine</kwd><kwd> Adolescents</kwd><kwd> Myopia Prevention and Control</kwd><kwd> Effectiveness</kwd><kwd> Safety</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：研究分析0.01%低浓度阿托品滴眼液在青少年近视防控中的疗效及安全性。方法：选取2020年4月~2021年4月在门诊就诊的青少年中低度近视(&lt;−6.0D)近视者120例，用数字随机法进行分两组各60例；对照组给予维生素B12滴眼液常规方法治疗；研究组给予0.01%阿托品滴眼液治疗，对比两组的临床治疗效果和安全性。结果：研究组治疗效果显著优于对照组，差异有统计意义(P &lt; 0.01)；控制眼轴的增幅也小于对照组，差异有统计意义(P &lt; 0.01)；两组不良反应发生率相比较差异较小，无统计意义(P &gt; 0.05)。结论：0.01%阿托品滴眼液在青少年近视防控中的效果及安全性均较好，值得临床推广使用。</p></sec><sec id="s2"><title>关键词</title><p>0.01%阿托品，青少年，近视防控，有效性，安全性</p></sec><sec id="s3"><title>Efficacy Analysis of Low Concentration Atropine Eye Drops in Prevention and Control of Myopia in Adolescents</title><p>Jianchu Sun<sup>1*</sup>, Xiaobo Gu<sup>2</sup>, Ying Wang<sup>2</sup>, Jianxun Guo<sup>2</sup>, Yuting Jiang<sup>2</sup></p><p><sup>1</sup>Guangzheng New Vision Eye Hospital, Wuxi Jiangsu</p><p><sup>2</sup>Qianqiao Street Community Health Service Center, Huishan District, Wuxi Jiangsu</p><p><img src="//html.hanspub.org/file/44-1572112x5_hanspub.png" /></p><p>Received: Apr. 25<sup>th</sup>, 2021; accepted: May 8<sup>th</sup>, 2021; published: May 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/44-1572112x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To study and analyze the efficacy and safety of 0.01% low concentration atropine eye drops in prevention and control of juvenile myopia. Methods: A total of 120 adolescent patients with moderate and low myopia (&lt;−6.00D) from April 2020 to April 2021 were selected and randomly divided into two groups with 60 cases in each group. The control group was treated with vitamin B<sub>12</sub> eye drops and the study group was treated with 0.01% atropine eye drops. The clinical efficacy and safety of the two groups were compared. Results: The treatment effect of the study group was significantly better than that of the control group; the difference was statistically significant (P &lt; 0.01). The increase of the control eye axis was also less than that of the control group, the difference was statistically significant (P &lt; 0.01); the difference in the incidence of adverse reactions between the two groups was small, there was no statistical significance (P &gt; 0.05). Conclusion: 0.01% atropine eye drops has good effect and safety in prevention and control of juvenile myopia, which is worthy of clinical application.</p><p>Keywords:0.01% Atropine, Adolescents, Myopia Prevention and Control, Effectiveness, Safety</p><disp-formula id="hanspub.42685-formula22"><graphic xlink:href="//html.hanspub.org/file/44-1572112x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/44-1572112x8_hanspub.png" /> <img src="//html.hanspub.org/file/44-1572112x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>近视是常见的屈光问题，也是引起视觉障碍的主要原因之一，随着科技的发展及生活习惯的改变，近视已成为全球范围内广泛关注的公共卫生问题，严重影响青少年的生理及心理健康 [<xref ref-type="bibr" rid="hanspub.42685-ref1">1</xref>]。据我国最近一项中小学生近视流行病学调查显示，近视患病率高达55.7%，明显高于西方国家 [<xref ref-type="bibr" rid="hanspub.42685-ref2">2</xref>]。研究表明，高度近视是视网膜脱离、青光眼、黄斑病变等致盲性眼病的危险因素，并且该风险随着近视程度的增加而增加。因此，为了降低这些致盲性眼病的风险，亟需采取有效的干预措施来减缓近视的进展 [<xref ref-type="bibr" rid="hanspub.42685-ref3">3</xref>]。我们自2020年4月~2021年4月对本院门诊就诊的青少年近视120例，随机分成二组，分别给予常规方式治疗和0.01% 阿托品滴眼液治疗，以此分析0.01%阿托品滴眼液用于青少年近视防治的安全性及有效性，争取为更多的青少年近视患者带来福音，现总结如下。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选取2020年4月~2021年4月于本院门诊的青少年中低度近视(&lt;−6.0D)近视120例，采用随机法分成研究组(n = 60，0.01%阿托品滴眼液治疗)和对照组(n = 60，维生素B12滴眼液治疗)，纳入标准：对研究组知情自愿参与，并经医学伦理委员会批准；排除标准：对本次研究所用阿托品药物有过敏､慢性眼表疾病､全身器质性疾病和临床资料不完善者｡分析入组者资料：近视时间(2.81 &#177; 1.25)年，基本均为中低度近视者(近视 &lt; 6.0D)。研究组男28例(46.67%)，女32例(53.33%)，年龄7~13 (平均9.15 &#177; 2.01)岁；对照组男29例(48.33%)，女31例(51.67%)，年龄7~12 (平均8.92 &#177; 1.94)岁｡两组资料比较：在性别､年龄、近视时间等临床资料对比差异无统计意义(P &gt; 0.05)。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>1) 对照组按常规方法治疗，使用维生素B12滴眼液(参天制药有限公司、国药准字J20150129)进行滴用，每晚睡前点1次，每次1滴；研究组自行配制滴眼液，将0.5 mg的硫酸阿托品注射液(天津金耀药业有限公司、国药准字H12020382) 1 ml加入4 ml玻璃酸钠滴眼液(参天制药有限公司、国药准字 H20173248)，配成0.01%阿托品滴眼液，每晚睡前点1次，每次1滴，持续治疗6~12个月。2) 设备：① 眼科光学生物测量仪选用德国Zelss (蔡司) IOL-Master 5.5进行眼光学生物测量，每3个月监测1次；② 电脑验光仪选用日本Topcon (拓普康) RM-8900进行检测；③ 检影镜选用苏州六六YZ-24带状光检影镜；④ 使用电脑自动验光仪和视网膜检影镜进行客观屈光状态的扩瞳(1%阿托品滴眼凝胶每日点2次，连续点5天)检影验光，每学期(半年)监测1次。</p></sec><sec id="s6_3"><title>2.3. 观察指标</title><p>疗效评定标准：1) 视力：单眼裸眼远视力 ≥ 5.0为显效，提高 ≥ 2行为有效，无改善为无效；总有效率 = (显效 + 有效)/总例数 &#215; 100% [<xref ref-type="bibr" rid="hanspub.42685-ref4">4</xref>]。2) 眼轴：增加幅度进行统计学比较；3) 不良反应的发生率：包括眼部不适、视物模糊、畏光、头晕等。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>统计学方法采用SPSS19.0统计软件进行处理分析。计量资料以 χ &#175; &#177; s 表示，计数资料以率(%)表示，两组间比较分别采用t检验和χ<sup>2</sup>检验。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 临床疗效比较治疗后的总有效率</title><p>研究组为96.67%，对照组为66.67% (χ<sup>2</sup> = 18.033, P = 0.000)，研究组总有效率明显高于对照组(见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of clinical efficacy between the two groups [cases (%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >显效</th><th align="center" valign="middle" >有效</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >总有效率</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >2 (3.33)</td><td align="center" valign="middle" >38 (63.34)</td><td align="center" valign="middle" >20 (33.33)</td><td align="center" valign="middle" >66.67</td></tr><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >2 (3.33)</td><td align="center" valign="middle" >56 (93.34)</td><td align="center" valign="middle" >2 (3.33)</td><td align="center" valign="middle" >96.67<sup>a</sup></td></tr></tbody></table></table-wrap><p>表1. 两组临床疗效比较[例(%)]</p><p>注：研究组与对照组总有效率比较，<sup>a</sup>P &lt; 0.01。</p></sec><sec id="s7_2"><title>3.2. 治疗前后眼轴长度比较</title><p>治疗前两组眼轴长度比较差异无统计学意义P &gt; 0.05；治疗后两组眼轴长度均有所增加，但研究组增加幅度小于对照组P &lt; 0.01 (见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of axial length before and after treatment between the two groups ( χ &#175; &#177; s, mm</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后</th><th align="center" valign="middle" >t值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >24.14 &#177; 1.11</td><td align="center" valign="middle" >26.52 &#177; 1.09</td><td align="center" valign="middle" >11.850</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >24.14 &#177; 1.11</td><td align="center" valign="middle" >25.26 &#177; 1.15</td><td align="center" valign="middle" >5.430</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >t值 P值</td><td align="center" valign="middle"  colspan="2"  >0.097 0.923</td><td align="center" valign="middle" >6.160 0.000</td><td align="center" valign="middle"  colspan="2"  ></td></tr></tbody></table></table-wrap><p>表2. 两组治疗前后眼轴长度比较( χ &#175; &#177; s, mm)</p></sec><sec id="s7_3"><title>3.3. 不良反应比较</title><p>两组不良反应发生率相比较差异较小，无统计意义P &gt; 0.05 (见表3)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of incidence of adverse reactions between the two groups [n (%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >眼部不适</th><th align="center" valign="middle" >视物模糊</th><th align="center" valign="middle" >畏光</th><th align="center" valign="middle" >头晕</th><th align="center" valign="middle" >总发生率</th></tr></thead><tr><td align="center" valign="middle" >对照组 研究组</td><td align="center" valign="middle" >60 60</td><td align="center" valign="middle" >2(4.00) 0(0.00)</td><td align="center" valign="middle" >0 (0.00) 2 (4.00)</td><td align="center" valign="middle" >0 (0.00) 2 (4.00)</td><td align="center" valign="middle" >2 (4.00) 0 (0.00)</td><td align="center" valign="middle" >4 (8.00) 4 (8.00)</td></tr></tbody></table></table-wrap><p>表3. 两组不良反应发生率比较[n(%)]</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>眼睛是人类感官中最重要的器官，尤其是在信息时代，大脑中约有80%的知识和记忆都是通过眼睛直接获取。我国是近视眼患病大国，近视人群比例达47%，近视的总患病人数已超过4亿。其中青少年近视眼患病率达50%~60%，居世界首位 [<xref ref-type="bibr" rid="hanspub.42685-ref5">5</xref>]。而在12~18岁这个阶段正是近视的高速发展时期，此时青少年学习任务繁重、压力最大、户外活动减少等均易导致近视发生。近年的研究发现，近视眼发病呈低龄化、且发展迅速，预计高度近视眼发病率将会增加，因此已成为严重影响青少年健康及生活质量的公共卫生问题。从长远看这对国家的经济、社会可持续发展及安全等都存在一个潜在的威胁。</p><p>阿托品是一种非选择性的M受体拮抗剂：最早用于治疗近视的药物，也是目前唯一经循证医学证实治疗近视有效的药物 [<xref ref-type="bibr" rid="hanspub.42685-ref6">6</xref>]。具有阻断胆碱能神经对睫状肌和瞳孔扩约肌的支配作用，可以有效地阻断调节及调节痉挛，所以过去曾认为其阻断近视的机制是由于调节麻痹，减少近视发展中过度调节的作用所致。但最近实验认为阿托品对实验性近视的阻断作用是通过作用于视网膜外组织(脉络膜、视网膜色素上皮、巩膜等)的M1和M4受体实现的 [<xref ref-type="bibr" rid="hanspub.42685-ref7">7</xref>]，从而影响巩膜重塑而延缓眼轴增长 [<xref ref-type="bibr" rid="hanspub.42685-ref8">8</xref>]。</p><p>阿托品疗效与浓度呈正相关系：1%浓度是最常见的治疗剂量，浓度越高近视控制效果则越好，但药物引起的不良反应也越明显 [<xref ref-type="bibr" rid="hanspub.42685-ref9">9</xref>]、依从性差；而0.01%浓度的阿托品能有效控制近视进展，且患者的依从性更好 [<xref ref-type="bibr" rid="hanspub.42685-ref10">10</xref>] ｡在我们研究观察中，研究组的总有效率58 (96.67)､无效率2 (3.33)､眼轴长度(25.26 &#177; 1.15) mm等均明显低于对照组的40 (66.67)､20 (33.33)､(26.52 &#177; 1.09) mm，差异有统计学意义(t = 6.160, P &lt; 0.01)，证明0.01%阿托品滴眼能够在一定程度上减缓近视度数的增加，并可减少高浓度阿托品引起的调节麻痹等不良反应，所以依从性也好。</p><p>阿托品的安全性及副作用分析：研究表明高浓度阿托品(1%)由于瞳孔被持续扩大后，畏光、视近物模糊、调节力降低等不良反应非常明显，因此依从性也差；另外也易发生过敏性结膜炎及长期瞳孔散大后可导致视网膜的光损害、白内障等并发症，以及停药后效果不易巩固而直接影响到临床的推广和应用。而低浓度阿托品可大幅度降低不良反应发生率，同时降低阿托品的给药浓度，可以提高患者的耐受性和依从性更好 [<xref ref-type="bibr" rid="hanspub.42685-ref11">11</xref>]。Copper等 [<xref ref-type="bibr" rid="hanspub.42685-ref12">12</xref>] 研究发现0.02%的阿托品是不引起临床症状的最佳浓度，瞳孔平均散大3 mm，调节力剩余8D以上，不会引起受试者的不适感。在我们所研究观察的两组病例里也证实没有明显差异，虽然出现了调节幅度有轻度下降，但仍然保存了足够的剩余调节力，因此并没有出现明显的近距离阅读困难和户外畏光、眩光等不适症状发生率均较为轻微，并随治疗时间延长症状消失，可能是由于机体出现药物耐受和代偿 [<xref ref-type="bibr" rid="hanspub.42685-ref13">13</xref>]。因不影响正常学习及生活，所以无需采取特殊治疗措施。</p><p>综上所述，阿托品控制近视的作用具有剂量效应，越强的近视控制常伴随越明显的副作用，而所有的这些风险都可以通过低浓度阿托品来缓解。研究表明0.01%低浓度阿托品可以有效缓解近视进展，并减少了高浓度阿托品引起的调节麻痹等副作用和停药后的反弹效应，对青少年近视的干预、应用是安全有效的。但由于我们研究的样本量还不大，随访观察时间也不长，还需持续和更进一步的深入研究探讨，它将为青年近视提供新的治疗方法和思路，值得临床推广使用。</p></sec><sec id="s9"><title>文章引用</title><p>孙建初,顾晓波,王 莺,郭建勋,蒋玉婷. 低浓度阿托品滴眼液在青少年近视防控中的疗效分析Efficacy Analysis of Low Concentration Atropine Eye Drops in Prevention and Control of Myopia in Adolescents[J]. 临床医学进展, 2021, 11(05): 2330-2334. https://doi.org/10.12677/ACM.2021.115335</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42685-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Pan, C.W., Wu, R.K., Liu, H., et al. (2018) Types of Lamp for Home Work and Myopia among Chinese School-Aged Children. Ophthalmic Epidemiology, 25, 250-256. &lt;br&gt;https://doi.org/10.1080/09286586.2017.1420204</mixed-citation></ref><ref id="hanspub.42685-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">陶芳标, 潘臣炜, 伍晓艳, 等. 户外活动防控儿童青少年近视专家推荐[J]. 中国学校卫生, 2019, 19(5): 641-643.</mixed-citation></ref><ref id="hanspub.42685-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">周佳, 马迎华, 马军, 等. 中国6省市中小学生近视流行现状及其影响因素分析[J]. 中华流行病学杂志, 2016, 37(1): 29-34.</mixed-citation></ref><ref id="hanspub.42685-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">翁俊杰. 阿托品类散瞳药物对近视的预防效果观察[J]. 医药前沿, 2018, 8(18): 148.</mixed-citation></ref><ref id="hanspub.42685-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">李建军. 近视眼防控与防盲模式蓝皮书(2015) [M]. 北京: 人民军医出版社, 2016.</mixed-citation></ref><ref id="hanspub.42685-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">许瑶, 曾骏文. 近视眼药物治疗研究进展[J]. 眼科新进展, 2013, 33(7): 691-693.</mixed-citation></ref><ref id="hanspub.42685-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Arumugam, B. and McBrien, N.A. (2012) Muscarinic Antagonist Control of Myopic: Evidence for M4 and M1 Recetor-Based Pathways in the Inhibition of Experimentally-Induced Axial Myopia in the Tree Shrew. Investigative Ophthalmology &amp; Visual Science, 53, 5827-5837. &lt;br&gt;https://doi.org/10.1167/iovs.12-9943</mixed-citation></ref><ref id="hanspub.42685-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Loughman, J. and Flitcroft, D.I. (2016) The Acceptability and Visual Impact of 0.01% Atropine in a Caucasian Population. British Journal of Ophthalmology, 100, 1525-1529. &lt;br&gt;https://doi.org/10.1136/bjophthalmol-2015-307861</mixed-citation></ref><ref id="hanspub.42685-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Chia, A., Lu, Q.S. and Tan, D. (2016) Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology, 123, 391-399. &lt;br&gt;https://doi.org/10.1016/j.ophtha.2015.07.004</mixed-citation></ref><ref id="hanspub.42685-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">钟瑞英, 王燕, 李坤梦, 等. 不同年龄及不同进展程度的近视患儿3种验光方法的选择时机[J]. 眼科新进展, 2018, 38(7): 660-663.</mixed-citation></ref><ref id="hanspub.42685-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">李静一, 刘芙蓉, 周晓伟, 等. 0.01%阿托品对学龄期儿童近视防控作用研究[J]. 中国学校卫生, 2018, 39(3): 432-435.</mixed-citation></ref><ref id="hanspub.42685-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cooper, J., Eisenberg, N., Schulman, E., et al. (2013) Maximum Atropine Dose without Clinical Signs or Symploms. Optometry and Vision Science, 90, 1467-1472. &lt;br&gt;https://doi.org/10.1097/OPX.0000000000000037</mixed-citation></ref><ref id="hanspub.42685-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">钟梅, 吕勇, 符爱存, 等. 质量分数0.01%和0.02%阿托品滴眼液对近视儿童瞳孔直径和调节幅度影响的一年随机､双盲､临床对照试验[J]. 中华实验眼科杂志, 2019, 37(7): 540-545.</mixed-citation></ref></ref-list></back></article>